Edesa Biotech updates $4.0M ATM stock program

Edesa Biotech, Inc. filed an 8-K to report that it has filed a new prospectus supplement supporting its at-the-market offering program for the offer and sale of up to $4,006,544 of common shares through H.C.

Rhea-AI Filing Summary

Edesa Biotech, Inc. filed an 8-K to report that it has filed a new prospectus supplement supporting its at-the-market offering program for the offer and sale of up to $4,006,544 of common shares through H.C. Wainwright & Co. as sales agent. This program operates under an existing At the Market Offering Agreement originally dated October 4, 2024.

The company has previously sold an aggregate of $837,134 of common shares under that agreement and an earlier prospectus supplement tied to a prior Form S-3 registration. The new prospectus supplement and base prospectus form part of a shelf registration statement on Form S-3 that was declared effective by the SEC on September 9, 2025, and a related legal opinion on the validity of the common shares is filed as an exhibit.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What capital raising step did Edesa Biotech (EDSA) disclose in this 8-K?

Edesa Biotech disclosed that it filed a new prospectus supplement to support its at-the-market offering program for the offer and sale of up to $4,006,544 of its common shares through H.C. Wainwright & Co. as sales agent.

How large is Edesa Biotechs current at-the-market capacity under the new prospectus supplement?

The new prospectus supplement covers the offer and sale of up to $4,006,544 of Edesa Biotech common shares from time to time under its at-the-market offering program.

How much has Edesa Biotech already sold under its existing at-the-market agreement?

Edesa Biotech has sold an aggregate of $837,134 of common shares pursuant to the At the Market Offering Agreement and a prior prospectus supplement dated October 4, 2024.

Which registration statement now governs Edesa Biotechs at-the-market offering?

The additional common shares offered under the at-the-market program are covered by Edesa Biotechs shelf registration statement on Form S-3 (File No. 333-288966), which was initially filed on July 25, 2025 and declared effective by the SEC on September 9, 2025.

Who acts as sales agent for Edesa Biotechs at-the-market offering?

H.C. Wainwright & Co., LLC serves as sales agent for Edesa Biotechs at-the-market offering program under the At the Market Offering Agreement dated October 4, 2024.

What legal opinion did Edesa Biotech file in connection with the at-the-market offering?

Edesa Biotech filed an opinion of Fasken Martineau DuMoulin LLP as Exhibit 5.1, covering the validity of the $4,006,544 of common shares that may be offered and sold under the agreement and related prospectus supplement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 04:35 PM Learn about SEC filing dates

false 0001540159 0001540159 2025-09-09 2025-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 9, 2025

Edesa Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

British Columbia, Canada		001-37619		N/A
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 Spy Court

Markham, Ontario, Canada L3R 5H6

(Address of Principal Executive Offices)

(289) 800-9600

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Shares		EDSA		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 9, 2025, Edesa Biotech, Inc. (the “Company”), filed a prospectus supplement (the “Prospectus Supplement”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s “at the market offering” program for the offer and sale of up to $4,006,544 of the Company’s common shares, without par value (the “Common Shares”), from time to time through H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to the Company’s existing At the Market Offering Agreement (the “ATM Agreement”), dated October 4, 2024. As of the date hereof, the Company has sold an aggregate of $837,134 of Common Shares pursuant to the ATM Agreement and the related prospectus supplement, dated October 4, 2024 to the Company’s Registration Statement on Form S-3 (333-266604).

The offer and sale of additional Common Shares by the Company under the ATM Agreement will be made pursuant to the Prospectus Supplement, dated September 9, 2025, and the accompanying base prospectus, dated September 9, 2025, contained therein, which together form a part of the Company’s shelf registration statement on Form S-3 (File No. 333-288966), initially filed with the SEC on July 25, 2025 and declared effective by the SEC on September 9, 2025 (the “Registration Statement”).

Fasken Martineau DuMoulin LLP, counsel to the Company, has issued a legal opinion relating to the validity of the $4,006,544 Common Shares that may be offered and sold pursuant to the ATM Agreement and related Prospectus Supplement. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:

Exhibit Number		Exhibit Description
5.1		Opinion of Fasken Martineau DuMoulin LLP
23.1		Consent of Fasken Martineau DuMoulin LLP (included in Exhibit 5.1)
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Edesa Biotech, Inc.
Date: September 9, 2025	By:	/s/ Peter Weiler
	Name:	Peter Weiler
	Title:	Chief Financial Officer